The number of individuals with Diabetes have shown continual growth over the years, from approximately 150 million in 2000, to 400 million in 2017. These figures are still rising. As cardiovascular disease is the primary complication of this condition, the high prevalence of Diabetes has greatly contributed to the global burden of cardiovascular diseases, with myocardial infarction being the leading cause of mortality among individuals with diabetes mellitus.
Many aspects of the pathophysiology of diabetes, such as inflammation and oxidative stress, are risk factors in the development of cardiovascular disease. Recent studies have demonstrated that new drugs like sodium/glucose cotransporter-2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP1a), that are used in the treatment of diabetes, have cardiovascular benefit. In addition, SGLT2i, drugs which are typically used to treat diabetes, have been successfully used in the treatment of heart failure in patients without diabetes. Frontiers in Cardiovascular Medicine have developed a special article collection with the aim of highlighting 'New Mechanisms and Drugs for The Treatment of Cardiovascular Disease with Diabetes'. The goal of this Research Topic is to provide insight on recent developments in the treatment of cardiovascular diseases in association with diabetes, and on its future challenges.
In this Research Topic, we aim to highlight novel potential therapeutic targets in the treatment of cardiovascular diseases in relation to diabetes. In addition, we would also like to discuss potential mechanisms that are involved in these diseases, including both clinical and basic studies. Finally, we would like to provide insights in novel research on the therapeutic potential of existing drugs for the treatment of cardiovascular disease in diabetes, such as SGLT2 inhibitors, GLP1a, DPP4 inhibitors, statins, and aspirin.
Frontiers in Cardiovascular Medicine encourages the submission of Original Research Articles (clinical or preclinical), Reviews, Mini Reviews and Case Reports. Original research articles include manuscripts reporting results from clinical investigations, including Phase I-III trials and population studies. Reports from experimental studies from related areas such as physiology, pathophysiology, cellular and molecular biology, genetics, or pharmacology may be considered as long as they relate to new understandings of pathogenic mechanisms or novel therapeutic approaches relevant to human disease.
The number of individuals with Diabetes have shown continual growth over the years, from approximately 150 million in 2000, to 400 million in 2017. These figures are still rising. As cardiovascular disease is the primary complication of this condition, the high prevalence of Diabetes has greatly contributed to the global burden of cardiovascular diseases, with myocardial infarction being the leading cause of mortality among individuals with diabetes mellitus.
Many aspects of the pathophysiology of diabetes, such as inflammation and oxidative stress, are risk factors in the development of cardiovascular disease. Recent studies have demonstrated that new drugs like sodium/glucose cotransporter-2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP1a), that are used in the treatment of diabetes, have cardiovascular benefit. In addition, SGLT2i, drugs which are typically used to treat diabetes, have been successfully used in the treatment of heart failure in patients without diabetes. Frontiers in Cardiovascular Medicine have developed a special article collection with the aim of highlighting 'New Mechanisms and Drugs for The Treatment of Cardiovascular Disease with Diabetes'. The goal of this Research Topic is to provide insight on recent developments in the treatment of cardiovascular diseases in association with diabetes, and on its future challenges.
In this Research Topic, we aim to highlight novel potential therapeutic targets in the treatment of cardiovascular diseases in relation to diabetes. In addition, we would also like to discuss potential mechanisms that are involved in these diseases, including both clinical and basic studies. Finally, we would like to provide insights in novel research on the therapeutic potential of existing drugs for the treatment of cardiovascular disease in diabetes, such as SGLT2 inhibitors, GLP1a, DPP4 inhibitors, statins, and aspirin.
Frontiers in Cardiovascular Medicine encourages the submission of Original Research Articles (clinical or preclinical), Reviews, Mini Reviews and Case Reports. Original research articles include manuscripts reporting results from clinical investigations, including Phase I-III trials and population studies. Reports from experimental studies from related areas such as physiology, pathophysiology, cellular and molecular biology, genetics, or pharmacology may be considered as long as they relate to new understandings of pathogenic mechanisms or novel therapeutic approaches relevant to human disease.
